Robaxin and Solu-cortef drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Robaxin (methocarbamol) and Solu-cortef (hydrocortisone sodium succinate). Common drug interactions include depression among females and erythema among males.

The phase IV clinical study analyzes what interactions people have when they take Robaxin and Solu-cortef. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Robaxin?

Robaxin has active ingredients of methocarbamol. It is often used in muscle spasms. eHealthMe is studying from 9,109 Robaxin users. Check the latest studies of Robaxin.

What is Solu-cortef?

Solu-cortef has active ingredients of hydrocortisone sodium succinate. eHealthMe is studying from 7,983 Solu-cortef users. Check the latest studies of Solu-cortef.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

11 people who take Robaxin and Solu-cortef together, and have interactions are studied.

Robaxin and Solu-cortef drug interactions.

What are the common drug interactions of Robaxin and Solu-Cortef, by gender? *:

female:

Depression
Injection site haemorrhage (bleeding from injection site)
Injection site urticaria (rash of round, red welts on the skin at injection site)
Limb injury
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
Poor venous access
Pruritus allergic (severe allergic itching of the skin)
Venous injury
Nausea (feeling of having an urge to vomit)
Venous thrombosis (blood clot (thrombus) that forms within a vein)

male:

Erythema (redness of the skin)

What are the common drug interactions of Robaxin and Solu-Cortef, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Abdominal pain
Confusional state
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
Nausea (feeling of having an urge to vomit)
Right ventricular failure (right half of the heart fails to work)
Septic shock (shock due to blood infection)
Skin wound
Somnolence (a state of near-sleep, a strong desire for sleep)
Vomiting

40-49:

n/a

50-59:

n/a

60+:

Abdominal distension
Arthralgia (joint pain)
Infusion related reaction
Myalgia (muscle pain)
Nausea (feeling of having an urge to vomit)
Oedema (fluid collection in tissue)
Onychalgia (nail biting)
Stomatitis (inflammation of mucous membrane of mouth)
Temperature intolerance (inability to go in temperature)
Therapeutic response decreased (less preventive response)

What are the existing conditions these people have? *

Immune System Disorder: 5 people, 45.45%
Nausea (feeling of having an urge to vomit): 2 people, 18.18%
Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 1 person, 9.09%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 1 person, 9.09%
Brain Neoplasm (tumour of brain): 1 person, 9.09%
Breakthrough Pain: 1 person, 9.09%
Cyst (a closed sac): 1 person, 9.09%
Diarrhea: 1 person, 9.09%
Hereditary Angioedema (recurrent episodes of severe swelling): 1 person, 9.09%
Immunoglobulins Abnormal: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Robaxin and Solu-cortef?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously